The purpose of this prospective trial was to study a combined-modality treatment including local consolidation by surgery or radiotherapy and high-dose chemotherapy (HDC) followed by peripheral-blood stem-cell (PBSC) transplantation. In all, 48 patients with oligometastatic breast cancer amenable to local treatment after induction chemotherapy with epirubicin and cyclophosphamide or paclitaxel and cisplatin, depending on prior adjuvant chemotherapy, were enrolled. The median follow-up was 41 months (range, 7-85 months). PBSC were collected in 47 patients, and 40 received one or two courses of HDC. Local therapy was given in 37 patients. No treatment-related deaths occurred. Of 47 evaluable patients, 36 (75% of intention-to-treat population) had no evidence of disease or complete remission after completion of therapy. Six patients (12.5%) had partial response, two patients (4%) no change, and three patients (6%) progressive disease. The median time to progression and overall survival was 17.5 (95% confidence interval (CI), 14-21 months) and 42.2 months (95% CI, 33-52 months), respectively, and 27% of patients were progression free after 5 years. In conclusion, patients with oligometastatic breast cancer can be treated safely with this combined modality protocol with promising relapse-free survivals.
bined modality
Metastatic breast cancer is usually regarded as an incurable disease, but long-term survival has been observed. 1 Greenberg et al 2 reported 17% complete remissions (CR) in 1581 patients treated with different protocols between 1973 and 1982. In all, 49 patients (3.1%) remained in CR for more than 5 years, and 26 patients (1.6%) survived a median of 191 months without recurrence. The long-term survivors included more premenopausal patients, a younger median age, a lower tumor burden, and a better performance status. The benefit of high-dose chemotherapy (HDC) in patients with breast cancer has been a subject of controversy for several years. [3] [4] [5] [6] Based on promising results of phase II studies, [7] [8] [9] several randomized trials for early and metastatic disease were started. However, the number of transplants has declined since early results of some of these studies showed no clear advantage of HDC over conventional-dose chemotherapy. [10] [11] [12] An analysis of the failure pattern showed that most patients relapse in sites of prior metastatic disease, indicating insufficient control of macroscopic disease by chemotherapy alone.
The concept of combining local treatment with intensified systemic consolidation chemotherapy could be an option to further improve these results in a subgroup of patients with limited, the so-called 'oligometastatic' disease. This means metastatic breast cancer limited to a single organ site, and mostly to a single lesion or few lesions, potentially resectable or curable with radiotherapy. 13 To study the feasibility of such an approach, we initiated a phase II intensified combined-modality protocol with conventional-dose induction chemotherapy followed by peripheral-blood stem-cell (PBSC) collection, local therapy with concomitant infusional 5-fluorouracil (5-FU)/folinic acid chemotherapy, and finally two courses of PBSCsupported consolidation HDC in patients with oligometastatic breast cancer.
Patients and methods

Patient population
In all, 48 women with histologically proven breast cancer were included in this prospective study. Further inclusion criteria were at least one-dimensional measurable disease, exclusion of CNS involvement, no prior therapy for metastatic disease, negative pregnancy test in women of child-bearing potential, biological age p50 years, adequate performance status (Karnofsky index X80%), sufficient hematological (WBC 43000/ml, platelet count 4100 000/ ml), renal and hepatic (creatinine and bilirubin o100% above UNL), and cardiac function (oNYHA III). Patients with lesions within a prior radiation field that seemed unresectable were excluded. Other exclusion criteria were known contraindications to any of the drugs of this trial, and other malignancies, with the exception of basal cell carcinoma or cervical carcinoma in situ. The study protocol including insurance coverage was approved by the University of Essen institutional review board and all patients gave written informed consent. The study was performed according to GCP guidelines and followed the declaration of Helsinki. ). Details about PBSC collection, cryopreservation, thawing, and transfusion have been described elsewhere. ), days 1-3. The second course of HDC was started on day 36 or after hematological restitution. Stem cells were transfused 2 days after completion of HDC and all patients received G-CSF (5 mg/kg body weight (bw)), thereafter. Packed red cell and platelet transfusions and antibiotics were given as indicated at the discretion of the treating physician. Leukocyte and platelet engraftment were defined as the first day with a WBC X1000/ml and platelets X20 000/ml, at least 2 days after the last platelet transfusion (first day of high-dose chemotherapy ¼ day 1). Evaluation of response and toxicity was performed according to the UICC and National Cancer Institute-Common Toxicity Criteria (NCI-CTC). High-dose chemotherapy in breast cancer P Bojko et al
Treatment protocol
Hormone therapy was allowed in receptor-positive patients after completion of therapy.
Radiotherapy
Patients were treated with megavoltage irradiation (5-15 MV photons). Thoracic target volumes (breast, mediastinum, supraclavicular region) were irradiated using isocentric parallel opposed fields or tangential fields. The dose was prescribed at isocenter depth. In the case of chest wall irradiation, radiotherapy treatment planning was performed using individual computed tomography scans. Vertebral metastases were irradiated by single static fields. The dose was prescribed at the dorsal edge of the vertebral body in the central axis. Doses less than or equal to 30 Gy were given in fractions of 3-4 Gy, five times per week. Higher doses were given in conventional fractions (5 Â 2 Gy/week). Tolerance doses of organs at risk (lung, brachial plexus, spinal cord) were respected. After 40 Gy, the spinal cord was entirely excluded from irradiation. Port film verifications were taken regularly once weekly.
Surgery
Surgery was performed for pulmonary, hepatic, lymphonodular and chest wall disease. Surgical procedures are summarized in Table 2 . Patients undergoing a primary operation had no microscopically proven total resection, and the intervention was usually performed to prove metastatic disease.
Statistical methods
Statistical calculations were carried out with the SPSS 10.0. (Chicago, IL, USA) and the Microsoft Excel 2000 software (Microsoft, Redmond, WA, USA). Survival curves were generated by the method of Kaplan-Meier, and comparisons of overall survival (OS) and time to progression (TTP) between different groups were made using the logrank test.
Results
Patients and treatment
Between February 1995 and March 2001, 48 female patients were enrolled in this study protocol (study was planned as a pilot study including 40-50 patients). Patient characteristics are summarized in Table 3 . The median follow-up is 41 months (range, 7-85 months). Induction chemotherapy consisted of epirubicin and cyclophosphamide in 27 (56%) patients and of paclitaxel and cisplatin in 21 (44%) patients. A total of 179 courses of induction chemotherapy were given, and each patient received a median of four courses of EC or TP (range, 3-6). G-CSF was administered for a median of 7 days (range, 5-10 days). Subsequently, a total of 68 PBSC collections were taken (median, one per patient; range, 1-4) and the median yield per patient was 6.9 Â 10 6 CD34 þ cells/kg bw (range, 2.0-24.3 Â 10 6 ). One patient had insufficient stem cells to undergo two courses of HDC, and another refused PBSC collection.
A total of 37 patients received local treatment. Of these, 11 women did not proceed to local therapy because the localization of metastases did not allow radiation or surgery. Radiotherapy was performed in 17 patients, and 13 underwent surgery. In five patients, surgery was performed before induction chemotherapy for tissue extraction and histological diagnosis. Two patients had surgery and radiotherapy. Tables 1 and 2 summarize local  treatment. A total of 40 patients received HDC. In two cases, a second HDC was omitted due to toxicity. In one patient, cyclophosphamide was replaced by melphalan during the first course of HDC because of prior hemorrhagic cystitis. Another woman had insufficient stem cells for a second course of HDC, and an additional course of conventionaldose epirubicin and cyclophosphamide was given instead. Eight patients did not receive HDC because of toxicity (n ¼ 3), progression (n ¼ 2), withdrawal of consent (n ¼ 2), and different histology after surgical resection (pulmonary carcinoid representing a secondary malignancy, n ¼ 1). After the first course of HDC, a median of 2.6 Â 10 
Toxicity and engraftment after HDC
There were no treatment-related deaths. During induction therapy 13 patients (27%) developed leukopenia grade 3 and 4 (EC, n ¼ 10; TP, n ¼ 3). Nonhematological toxicity 
Response and survival
After induction chemotherapy, 12 patients (25%) had no evidence of disease or a CR, 24 patients (50%) had a partial response, and 12 patients (25%) no change. No patient had progressive disease. After local treatment, 23 patients (48%) had no evidence of disease or CR, four patients (8.3%) reached a partial remission and one patient had stable disease, while two women (4.2%) showed progressive disease.
After completion of all treatment modalities, 36 patients (75%) had no evidence of disease or a CR, six patients (12.5%) achieved a partial remission, and two patients (4.2%) had no change, while three (6.3%) had progressive disease. One woman who had not had HDC could not be evaluated. Overall response after completion of therapy is shown in Table 4 . The median TTP was 17.5 months (95% confidence interval (CI), 13.8-21.3 months) and median OS was 42.2 months (95% CI, 32.6-51.8 months).
After 3 and 5 years, the percentage of progression-free patients is 31 and 27%, respectively, and 62 and 37% of all patients are still alive. The Kaplan-Meier plots of OS and TTP are shown in Figures 2 and 3 .
Subgroup analyses were performed between patients receiving induction chemotherapy with EC or TP and between those who had local treatment or not according to the site of metastases (bone or liver). None of these analyses showed significant differences in the median TTP and OS.
A total of 19 patients received hormone treatment after completion of HDC: tamoxifen (n ¼ 10), tamoxifen plus goserelin (n ¼ 3), medroxyprogesterone acetate (n ¼ 3), anastrozole (n ¼ 2), and letrozole (n ¼ 1). During follow-up, recurrence was seen in 35 patients. In total, 14 women relapsed at the initial localization and 11 women at the primary and a distant tumor site. In 10 patients the disease recurred at new localizations, only. Four women developed brain metastases.
Discussion
The introduction of systemic treatment with chemotherapy, hormone, and antibody therapy plus radiotherapy has improved the outcome of patients with early and advanced breast cancer, and guidelines for different stages of the disease have been established. 15, 16 However, patients with metastatic disease are usually regarded as incurable, although a few long-term survivors are observed. 2 To date, stem cell supported HDC has not proven superior as compared to conventional-dose therapy. Stadtmauer et al 11 treated 553 patients with four to six cycles of standard chemotherapy. In all, 58 (11%) and 252 (46%) patients had a complete and partial response, respectively, and were randomized to either HDC or further conventional-dose chemotherapy. The median TTP did not differ between the two groups (9.6 vs 9.0 months) and many programs including HDC in metastatic breast cancer have been stopped since then.
Metastatic breast cancer usually presents as disseminated disease, limiting local treatment to a small number of patients. However, Kamby and Sengelov 17 observed about 30% long-term survivors after local treatment alone in 140 patients with isolated locoregional recurrence. While radiotherapy is quite common in patients with symptomatic metastatic disease, the benefit of surgical resection of distant metastases is still a matter of debate due to the systemic character of the disease, and despite some encouraging reports, especially from patients with hepatic and pulmonary disease. [18] [19] [20] To combine local with intensified systemic treatment, we initiated the pilot trial presented here with dose-intensive induction chemotherapy, peripheral-blood stem-cell collection, local treatment in combination with infusional 5-FU plus folinic acid, and two subsequent courses of HDC. The addition of infusional 5-FU plus folinic acid to local treatment was used for better systemic control based on encouraging results of this schedule even in anthracyclineresistant disease. 21, 22 The overall tolerability of this combined-modality regimen was acceptable and there were no unexpected side effects or treatment-related deaths. Only one patient had grade 4 5-FU-related toxicity and did not proceed to HDC.
The median TTP and OS were promising at 17.5 and 42.2 months, but were inferior to the results reported by Nieto et al 23 with corresponding values of 52 and 80 months. However, in their study, patients with liver metastases were excluded, while 14 (29%) of our patients had hepatic involvement. Interestingly, the outcome of this subgroup did not differ from the remaining patients in the study presented here. The same observation was made in patients with or without bone metastases, the inclusion of whom was a matter of debate at the initiation of this study. However, because of the already small number of the whole group of these selected patients, any subset analysis must be interpreted very cautiously. High-dose chemotherapy in breast cancer P Bojko et al
The sites of recurrence were equally distributed to same, distant, or both locations as compared with the primary metastatic localization, indicating that both local and systemic therapy failed in these cases. No further subgroup analyses for HER-2 expression (not routinely performed at this time), number of sites, and primary nodal ratio were performed, which turned out to be independent outcome predictors in the study performed by Nieto et al. 23 However, the rather small number of 60 patients included in their study must also be kept in mind, before general conclusions about prognostic factors can be drawn.
Patients who relapsed after HDC were offered subsequent treatment, which seems to be a rational approach based on our own experience with other patients relapsing after intensive treatment protocols. 24 In the study presented here, a 2 year difference between TTP and OS was achieved.
Patients with unresectable liver metastases from colorectal cancer showed very good long-term results if surgical resection of hepatic lesions after primary chemotherapy was possible. 25 To date, there have been only very few data concerning such combined-modality therapies in the treatment of limited metastatic breast cancer. The results of this study suggest that local treatment combined with intensified systemic consolidation chemotherapy may be a useful and well-tolerated option in a selected group of patients with oligometastatic breast cancer leading to 27% relapsefree survival after 5 years.
The benefit of conventional-dose adjuvant doxorubicinbased chemotherapy after local treatment of stage IV breast cancer patients has been shown in a retrospective trial performed at the MD Anderson Cancer Center. 26 Confirmation of these results by randomized trials including larger patient numbers with defined prognostic factors should be considered. However, to offer this treatment modality to selected patients, early detection of metastatic disease would be mandatory, necessitating intensive postoperative monitoring after primary treatment has been completed. 13, 27 
